{"id":"im-aripiprazole-once-monthly","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"10-15","effect":"Akathisia"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Anxiety"},{"rate":"5-10","effect":"Insomnia"},{"rate":"5-10","effect":"Weight gain"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL2219425","moleculeType":"Small molecule","molecularWeight":"660.73"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aripiprazole acts as a partial agonist at dopamine D2 and D3 receptors, providing dopaminergic stabilization rather than pure antagonism. This mechanism reduces excessive dopamine signaling in hyperactive pathways while maintaining adequate dopamine function in hypoactive pathways. The intramuscular once-monthly formulation provides sustained drug delivery for improved medication adherence in psychiatric patients.","oneSentence":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat schizophrenia and bipolar disorder.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:05.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Schizophrenia"},{"name":"Bipolar I disorder (maintenance treatment)"},{"name":"Agitation associated with schizophrenia or bipolar disorder"}]},"trialDetails":[{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT03839251","phase":"PHASE4","title":"Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2018-06-01","conditions":"Schizophrenia","enrollment":82},{"nctId":"NCT02146547","phase":"PHASE4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2015-02","conditions":"Schizophrenia","enrollment":536},{"nctId":"NCT02697045","phase":"PHASE4","title":"Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch","status":"COMPLETED","sponsor":"Abdi İbrahim Otsuka","startDate":"2017-01-04","conditions":"Schizophrenia","enrollment":23},{"nctId":"NCT01567527","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2012-08","conditions":"Bipolar I Disorder","enrollment":731},{"nctId":"NCT01795547","phase":"PHASE3","title":"Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-02","conditions":"Schizophrenia","enrollment":295},{"nctId":"NCT01959035","phase":"PHASE3","title":"Aripiprazole Once-monthly in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2013-10","conditions":"Schizophrenia","enrollment":88},{"nctId":"NCT01683058","phase":"PHASE3","title":"Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2013-01","conditions":"Schizophrenia","enrollment":74}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IM aripiprazole once monthly","genericName":"IM aripiprazole once monthly","companyName":"University of Utah","companyId":"university-of-utah","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aripiprazole is a dopamine D2/D3 receptor partial agonist that modulates dopaminergic and serotonergic neurotransmission to treat schizophrenia and bipolar disorder. Used for Schizophrenia, Bipolar I disorder (maintenance treatment), Agitation associated with schizophrenia or bipolar disorder.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}